APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic casesHélène-Marie Lanoiselée, Gaël Nicolas, David Wallon et al.|PLoS Medicine|2017Cited by 610
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s diseaseStephen Salloway, Paul Aisen, Andrew J. Aschenbrenner et al.|Nature Medicine|2021Cited by 365
Amyloid‐Related Imaging Abnormalities in the <scp>DIAN‐TU</scp>‐001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer DiseaseNelly Joseph‐Mathurin, Richard J. Perrin, Jorge J. Llibre‐Guerra et al.|Annals of Neurology|2022Cited by 42
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trialRandall J. Bateman, Bruno Dubois, Yan Li et al.|The Lancet Neurology|2025Cited by 39
Le phénotype clinique initial a-t-il un impact sur le pronostic dans la maladie à corps de Lewy ?Clément Aveneau, Claire Paquet, David Wallon et al.|Revue Neurologique|2024Cited by 0